Testosterone treatment in men with osteoporosis and subnormal serum testosterone levels
Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. Haider A, Meergans U, Traish A, et al. Int J Endocrinol 2014; Article ID: 496948
Testosterone treatment can have a beneficial effect on bone loss resulting from testosterone deficiency. This summary discusses the key findings from a long-term, observational, open-label, prospective, cumulative, registry study that investigated the use of parenteral testosterone undecanoate (TU) 1,000 mg/12 weeks in hypogonadal men with osteoporosis.1 Bone mineral density (BMD), expressed as a T-score in 45 men (mean age 53 ± 7 years) was measured over the six year period of TU treatment.
What is known
Osteoporosis in men is a condition that is often underdiagnosed and undertreated.2 Although men tend to have higher BMD than women, and hence a lower incidence of fractures, fracture related mortality and morbidity are more frequent in men, partly due to greater frailty.3 Testosterone is believed to play a significant role in the maintenance of BMD.4 Testosterone deficiency (TD) has been associated with a reduction in BMD in men and testosterone treatment has been shown to improve BMD in men with subnormal testosterone levels.5 A recent study in men <50 years with TD and experiencing infertility or sexual dysfunction, found that over one-third of these patients also had reduced BMD.6 Improvements in BMD were observed following treatment of these patients with testosterone for 2.5 years. The results of this study provide further support for the routine measurement of BMD in relatively young men with subnormal testosterone levels.
What this study adds
This is the first long-term (6-year follow-up) study in men with osteoporosis treated with 1,000 mg TU and demonstrates that TU significantly improves T-scores associated with BMD in men with osteoporosis and TD.1 These results complement findings from several studies that have reported beneficial effects of testosterone treatment on BMD in hypogonadal men.7-13 Despite a number of conditions being responsible for patients’ TD (including Klinefelter’s syndrome, other forms of primary hypogonadism, alcohol abuse and Crohn’s disease), they all saw progressive increases in T-scores, with osteoporosis improving to a classification of osteopenia (Figure).1 Many of the patients included in this study were found to have Klinefelter’s syndrome, a condition which had previously remained undiagnosed. These findings support routine testing for TD in men with osteoporosis to enable effective treatment with testosterone in men with subnormal testosterone levels.
A number of other pathologies including metabolic effects, inflammation and erectile dysfunction have also been associated with chronic TD.14,15 In the current study, significant improvements in lipid profiles over the 6 year period were also observed following TU treatment, including statistically significant increases in HDL-C and statistically significant decreases in LDL-C, total cholesterol and triglycerides.1 Blood levels of an inflammatory biomarker, CRP, were also significantly decreased. In addition, significant and progressive improvements in male aging symptoms and erectile function were also observed.
Whilst the findings of this study merit further exploration, there are some limitations to be noted. This was a long-term, open-label, observational, and uncontrolled study which was not primarily designed to monitor the effects of normalizing serum testosterone on BMD in hypogonadal men with osteoporosis. Biomarkers of bone remodeling were not measured as there was not expected to be such a large number of patients with osteoporosis identified as having TD. As such, longitudinal, placebo-controlled, randomized trials are warranted to understand the role of TU treatment in hypogonadal men with osteoporosis.